ARFONAD
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Apr 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARFONAD is an injectable small-molecule product approved by Roche in 1954 for an undisclosed indication. The specific mechanism of action and therapeutic area are not documented in available sources, limiting clinical context.
LOE Approaching
Product is approaching loss of exclusivity with minimal market data; career growth limited by unclear commercial trajectory and 0 linked positions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal minimal hiring; working on ARFONAD offers limited career mobility or advancement opportunity. This is a legacy product with declining strategic priority at Roche.
Brand ManagerField Sales Representative
Worked on ARFONAD at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.